{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T20:15:37Z","timestamp":1794773737087,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In real-world scenarios, Janus Kinase (JAK) inhibitors are often offered to \"difficult-to-treat\" rheumatoid arthritis patients, quite different from those included in randomized controlled trials. Our study aimed to evaluate the influence of patient-related factors on the effectiveness and safety of JAK inhibitors in real-world clinical practice. This observational retrospective study involved rheumatoid arthritis patients who received treatment with either tofacitinib, baricitinib, upadacitinib, or filgotinib. At 12\u00a0months of treatment, reasons for and rates of JAK inhibitor treatment discontinuation were examined. Treatment retentions were analyzed through Cox proportional hazard regression models and Kaplan\u2013Meier estimates. Patient-related factors that could influence treatment retention were evaluated for the discontinuation reasons of lack of effectiveness and adverse events. At 12\u00a0months of treatment, discontinuation rates for 189 JAK inhibitor treatments were: lack of effectiveness (24.3%), adverse events (20.6%), and other reasons (3.7%). The remaining 51.4% represents the treatment continuation rate. No patient-related factors evaluated had an influence on treatment discontinuation due to lack of effectiveness. Ae significantly increased the risk of treatment discontinuation due to adverse events (p\u2009=\u20090.030). In terms of age, at 12\u00a0month of treatment, discontinuation rates due to adverse events were:\u2009&lt;\u200965\u00a0years, 14.4% vs. 65\u00a0years or older, 26.3% (p\u2009=\u20090.019). Rheumatoid arthritis patients aged 65\u00a0years or older showed an increased risk of JAK inhibitor treatment discontinuation due to adverse events. Factors not related to treatment discontinuation were: sex, rheumatoid arthritis disease duration, rheumatoid arthritis disease activity, seropositivity for rheumatoid factor, seropositivity for anti-cyclic citrullinated peptides, number of prior biologic treatments, number of prior JAK inhibitor treatments, concomitant use of glucocorticoids, and concomitant use of conventional synthetic disease-modifying antirheumatic drugs.<\/jats:p>","DOI":"10.1038\/s41598-023-50379-8","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T13:02:42Z","timestamp":1704200562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5079-613X","authenticated-orcid":false,"given":"Cristina","family":"Martinez-Molina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-6588","authenticated-orcid":false,"given":"Ignasi","family":"Gich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6275-7699","authenticated-orcid":false,"given":"Cesar","family":"Diaz-Torn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4972-9527","authenticated-orcid":false,"given":"Hye S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2074-2231","authenticated-orcid":false,"given":"Anna","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3909-6682","authenticated-orcid":false,"given":"Silvia","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7738-6787","authenticated-orcid":false,"given":"H\u00e8ctor","family":"Corominas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"50379_CR1","doi-asserted-by":"publisher","unstructured":"Aletaha, D. & Smolen, J. S. Diagnosis and management of rheumatoid arthritis: A review. JAMA. 320(13), 1360\u20131372. https:\/\/doi.org\/10.1001\/jama.2018.13103 (2018).","DOI":"10.1001\/jama.2018.13103"},{"key":"50379_CR2","doi-asserted-by":"publisher","unstructured":"McInnes, IB. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365(23), 2205\u20132219. https:\/\/doi.org\/10.1056\/NEJMra1004965 (2011).","DOI":"10.1056\/NEJMra1004965"},{"key":"50379_CR3","doi-asserted-by":"publisher","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82(1), 3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356 (2023).","DOI":"10.1136\/ard-2022-223356"},{"issue":"7","key":"50379_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel, L. et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 73(7), 924\u2013939. https:\/\/doi.org\/10.1002\/acr.24596 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"50379_CR5","doi-asserted-by":"publisher","unstructured":"Fleischmann, R. et al. ORAL-Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367(6), 495\u2013507. https:\/\/doi.org\/10.1056\/NEJMoa1109071 (2012).","DOI":"10.1056\/NEJMoa1109071"},{"key":"50379_CR6","doi-asserted-by":"publisher","unstructured":"Kremer, J. et al. ORAL-Sync Investigators. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 159(4), 253\u2013261. https:\/\/doi.org\/10.7326\/0003-4819-159-4-201308200-00006 (2013).","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"50379_CR7","doi-asserted-by":"publisher","unstructured":"Van Vollenhoven, R. F. et al. ORAL-Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367(6), 508\u2013519. https:\/\/doi.org\/10.1056\/NEJMoa1112072 (2012).","DOI":"10.1056\/NEJMoa1112072"},{"key":"50379_CR8","doi-asserted-by":"publisher","unstructured":"Van der Heijde, D. et al. ORAL-Scan Investigators. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 65(3), 559\u2013570. https:\/\/doi.org\/10.1002\/art.37816 (2013).","DOI":"10.1002\/art.37816"},{"key":"50379_CR9","doi-asserted-by":"publisher","unstructured":"Burmester, G. R. et al. ORAL-Step Investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet. 381(9865), 451\u2013460. https:\/\/doi.org\/10.1016\/S0140-6736(12)61424-X (2013).","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"50379_CR10","doi-asserted-by":"publisher","unstructured":"Lee, EB. et al. ORAL-Start Investigators. Tofacitinib versus methotrexate in rheumatoid arthritis. N. Engl. J. Med. 370(25), 2377\u20132386. https:\/\/doi.org\/10.1056\/NEJMoa1310476 (2014).","DOI":"10.1056\/NEJMoa1310476"},{"key":"50379_CR11","doi-asserted-by":"publisher","unstructured":"Fleischmann, R. et al. ORAL-Strategy Investigators. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): A phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 390(10093), 457\u2013468. https:\/\/doi.org\/10.1016\/S0140-6736(17)31618-5 (2017).","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"50379_CR12","doi-asserted-by":"publisher","unstructured":"Fleischmann, R. et al. RA-BEGIN Investigators. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 69(3), 506\u2013517. https:\/\/doi.org\/10.1002\/art.39953 (2017).","DOI":"10.1002\/art.39953"},{"key":"50379_CR13","doi-asserted-by":"publisher","unstructured":"Taylor, P. C. et al. RA-BEAM Investigators. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N. Engl. J. Med. 376(7), 652\u2013662. https:\/\/doi.org\/10.1056\/NEJMoa1608345 (2017).","DOI":"10.1056\/NEJMoa1608345"},{"key":"50379_CR14","doi-asserted-by":"publisher","unstructured":"Dougados, M. et al. RA-BUILD Investigators. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study. Ann. Rheum. Dis. 76(1), 88\u201395. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210094 (2017).","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"50379_CR15","doi-asserted-by":"publisher","unstructured":"Genovese, M. C. et al; RA-BEACON Investigators. Baricitinib in patients with refractory rheumatoid arthritis. N. Engl. J. Med. 374(13), 1243\u20131252. https:\/\/doi.org\/10.1056\/NEJMoa1507247 (2016).","DOI":"10.1056\/NEJMoa1507247"},{"key":"50379_CR16","doi-asserted-by":"publisher","unstructured":"Van Vollenhoven, R. et al. SELECT-EARLY Investigators. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): A multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol. 72(10), 1607\u20131620. https:\/\/doi.org\/10.1002\/art.41384 (2020).","DOI":"10.1002\/art.41384"},{"key":"50379_CR17","doi-asserted-by":"publisher","unstructured":"Smolen, J. S. et al. SELECT-MONOTHERAPY Investigators. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): A randomised, placebo-controlled, double-blind phase 3 study. Lancet. 393(10188), 2303\u20132311. https:\/\/doi.org\/10.1016\/S0140-6736(19)30419-2 (2019).","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"50379_CR18","doi-asserted-by":"publisher","unstructured":"Burmester, G. R. et al. SELECT-NEXT Investigators. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 391(10139), 2503\u20132512. https:\/\/doi.org\/10.1016\/S0140-6736(18)31115-2 (2018).","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"50379_CR19","doi-asserted-by":"publisher","unstructured":"Fleischmann, R. et al. SELECT-COMPARE Investigators. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 71(11), 1788\u20131800. https:\/\/doi.org\/10.1002\/art.41032 (2019).","DOI":"10.1002\/art.41032"},{"key":"50379_CR20","doi-asserted-by":"publisher","unstructured":"Genovese, M. C. et al. SELECT-BEYOND Investigators. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial. Lancet. 391(10139), 2513\u20132524. https:\/\/doi.org\/10.1016\/S0140-6736(18)31116-4 (2018).","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"50379_CR21","doi-asserted-by":"publisher","unstructured":"Rubbert-Roth, A. et al. SELECT-CHOICE Investigators. Trial of upadacitinib or abatacept in rheumatoid arthritis. N. Engl. J. Med. 383(16), 1511\u20131521. https:\/\/doi.org\/10.1056\/NEJMoa2008250 (2020).","DOI":"10.1056\/NEJMoa2008250"},{"key":"50379_CR22","doi-asserted-by":"publisher","unstructured":"Combe, B. et al. FINCH-1 Investigators. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: A phase III randomised clinical trial. Ann. Rheum Dis. 80(7), 848\u2013858. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219214 (2021).","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"50379_CR23","doi-asserted-by":"publisher","unstructured":"Genovese, M. C. et al; FINCH-2 Investigators. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: The FINCH 2 randomized clinical trial. JAMA. 322(4), 315\u2013325. https:\/\/doi.org\/10.1001\/jama.2019.9055 (2019).","DOI":"10.1001\/jama.2019.9055"},{"key":"50379_CR24","doi-asserted-by":"publisher","unstructured":"Westhovens, R. et al. FINCH-3 Investigators. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: The phase 3, randomised controlled FINCH 3 trial. Ann. Rheum. Dis. 80(6), 727\u2013738. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219213 (2021).","DOI":"10.1136\/annrheumdis-2020-219213"},{"issue":"2","key":"50379_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/2229-516X.157148","volume":"5","author":"R Mahajan","year":"2015","unstructured":"Mahajan, R. Real world data: Additional source for making clinical decisions. Int. J. Appl. Basic Med. Res. 5(2), 82. https:\/\/doi.org\/10.4103\/2229-516X.157148 (2015).","journal-title":"Int. J. Appl. Basic Med. Res."},{"key":"50379_CR26","doi-asserted-by":"publisher","unstructured":"Sherman, RE. et al. Real-world evidence - What is it and what can it tell us? N Engl J Med. 375(23), 2293\u20132297. https:\/\/doi.org\/10.1056\/NEJMsb1609216 (2016).","DOI":"10.1056\/NEJMsb1609216"},{"key":"50379_CR27","doi-asserted-by":"publisher","unstructured":"Nagy, G. et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 80(1), 31\u201335. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217344 (2021).","DOI":"10.1136\/annrheumdis-2020-217344"},{"key":"50379_CR28","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League against rheumatism collaborative initiative. Ann. Rheum Dis. 69, 1580\u20131588. https:\/\/doi.org\/10.1136\/ard.2010.138461 (2010).","journal-title":"Ann. Rheum Dis."},{"issue":"1","key":"50379_CR29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41598-021-04075-0","volume":"12","author":"K Ebina","year":"2022","unstructured":"Ebina, K. et al. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: The ANSWER cohort study. Sci. Rep. 12(1), 134. https:\/\/doi.org\/10.1038\/s41598-021-04075-0 (2022).","journal-title":"Sci. Rep."},{"key":"50379_CR30","unstructured":"Curtis, J. R. et al. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 35(3), 390\u2013400 (2017)."},{"issue":"2","key":"50379_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000546","volume":"3","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann, R. et al. Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis. RMD Open. 3(2), e000546. https:\/\/doi.org\/10.1136\/rmdopen-2017-000546 (2017).","journal-title":"RMD Open."},{"key":"50379_CR32","doi-asserted-by":"publisher","unstructured":"Kristensen, L. E. et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: An analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 82(7), 901\u2013910. https:\/\/doi.org\/10.1136\/ard-2022-223715 (2023).","DOI":"10.1136\/ard-2022-223715"},{"key":"50379_CR33","unstructured":"European Medicines Agency \u2013 EMA (2023). EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. EMA\/142279\/2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki. Accessed 22 May 2023."},{"issue":"2","key":"50379_CR34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/ard-2022-222835","volume":"82","author":"M Pombo-Suarez","year":"2023","unstructured":"Pombo-Suarez, M. et al. After JAK inhibitor failure: To cycle or to switch, that is the question\u2014data from the JAK-pot collaboration of registries. Ann. Rheum. Dis. 82(2), 175\u2013181. https:\/\/doi.org\/10.1136\/ard-2022-222835 (2023).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"50379_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000742","volume":"5","author":"P Bird","year":"2019","unstructured":"Bird, P. et al. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib. RMD Open. 5(1), e000742. https:\/\/doi.org\/10.1136\/rmdopen-2018-000742 (2019).","journal-title":"RMD Open."},{"key":"50379_CR36","doi-asserted-by":"publisher","unstructured":"Retuerto, M. et al. Efficacy and safety of switching Jak inhibitors in rheumatoid arthritis: An observational study. Clin. Exp. Rheumatol. 39(3), 453\u2013455. https:\/\/doi.org\/10.55563\/clinexprheumatol\/cbanza (2021).","DOI":"10.55563\/clinexprheumatol\/cbanza"},{"issue":"11","key":"50379_CR37","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1002\/art.38779","volume":"66","author":"S Cohen","year":"2014","unstructured":"Cohen, S. et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 66(11), 2924\u20132937. https:\/\/doi.org\/10.1002\/art.38779 (2014).","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"50379_CR38","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.3390\/jcm12051734","volume":"12","author":"R Sanmart\u00ed","year":"2023","unstructured":"Sanmart\u00ed, R. & Corominas, H. Upadacitinib for patients with rheumatoid arthritis: A comprehensive review. J. Clin. Med. 12(5), 1734. https:\/\/doi.org\/10.3390\/jcm12051734 (2023).","journal-title":"J. Clin. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50379-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50379-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50379-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T13:12:28Z","timestamp":1704201148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50379-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50379"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-50379-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"13 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. HC has received speaker honoraria from Gr\u00fcnenthal, MSD, Biogen, Galapagos, Abbvie, Roche, and Bristol Myers Squibb and consultancy\/lectures fees from Galapagos, Gebro, Abbvie, Sanofi, and UCB. Other authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"172"}}